S-1/A: Encore Medical IPO: Funding US Clinical Trials Amid Losses

Sentiment:

Initial Public Offering Registration Statement 30 December 2025 4:03 PM

Encore Medical, a structural heart device company, is launching an IPO to raise $12.96 million for critical US clinical trials for stroke and migraine indications, despite a history of net losses and going concern doubts.

Delay expectedThe company's US clinical trial for PFO septal occlusion device for stroke is expected to take approximately two years to complete, with no assurance of timely completion or sufficient results for FDA approval.Clinical trial expenses decreased significantly for the nine months ended September 30, 2025, due to limited resources, indicating prior delays in trial advancement due to funding constraints.

Capital raiseThe company is undertaking an initial public offering (IPO) to sell 3,000,000 shares of common stock at an assumed price of $5.00 per share, aiming to raise approximately $12,960,000 in net proceeds.The company has granted underwriters an over-allotment option to purchase up to an additional 450,000 shares, potentially increasing net proceeds to $14,880,000.Management explicitly states that the net proceeds from this offering alone will not be sufficient to complete a US trial for migraine indications through full regulatory approval, implying a need for future capital raises.The independent auditor's going concern opinion highlights the necessity of raising additional capital to fund the business plan and sustain operations beyond the next fiscal year.The company has outstanding unsecured convertible promissory notes totaling $350,000, which are convertible into common stock at $5.00 per share at the option of the holder prior to repayment.An existing lender (Merit Medical Systems, Inc.) holds a right of first offer with respect to future equity or debt financings until November 6, 2028, which could influence future capital raising efforts.

Worse than expectedThe company has incurred recurring net losses since inception, including $1,845,951 in 2024 and $557,566 for the nine months ended September 30, 2025.An accumulated deficit of $6,448,446 and negative working capital of $398,878 as of September 30, 2025, indicate a precarious financial position.The independent auditor has included an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern.Revenue for the nine months ended September 30, 2025, decreased by 16.4% compared to the same period in 2024, attributed to limited cash resources and focus on IPO activities rather than operational growth.

Summary

Encore Medical, Inc. proposes to issue and sell 3,000,000 shares of common stock in its initial public offering at an assumed price of $5.00 per share, aiming to raise approximately $12,960,000 in net proceeds.
The company has granted underwriters an option to purchase up to an additional 450,000 shares to cover over-allotments, which could increase net proceeds to approximately $14,880,000.
Proceeds are primarily allocated to finance US clinical trials for PFO septal occlusion devices for stroke ($7.2 million) and migraine indications ($2.0 million), with remaining funds for sales/marketing ($1.5-$2.0 million), equipment ($1.2 million), and general working capital ($1.1-$2.5 million).
Encore Medical develops, manufactures, and markets septal occlusion products for cardiac defects, with approximately 35,000 implants outside the US to date.
The company holds CE Mark approval for its products in Europe and other international markets, generating substantially all its current revenue from these regions.
An Investigational Device Exemption (IDE) has been granted by the FDA to conduct a Class III clinical trial in the US for its PFO septal occlusion device for stroke, expected to take 18-24 months to complete.
A separate clinical study is underway in Europe for the migraine indication, with plans to seek US FDA IDE approval upon successful conclusion.
Encore Medical has incurred net losses since inception, with a net loss of $1,845,951 for the year ended December 31, 2024, and $557,566 for the nine months ended September 30, 2025.
As of September 30, 2025, the company had an accumulated deficit of $6,448,446 and negative working capital of $398,878, leading its independent auditor to raise substantial doubt about its ability to continue as a going concern.
The company's capitalization as of September 30, 2025, on a pro forma as adjusted basis after the offering, would include $13,010,000 in cash and total stockholders' equity of $11,706,720.
Existing shareholders will experience immediate and substantial dilution, with new investors contributing 71.7% of the aggregate price paid for approximately 30.8% of outstanding common stock.
The company has outstanding debt, including a $1,000,000 secured promissory note maturing November 6, 2026, and $350,000 in unsecured convertible promissory notes maturing June 30, 2026.
The company's authorized common stock will increase from 10,000,000 to 20,000,000 shares, and Series A Preferred Stock will convert to common stock immediately prior to the offering's closing.

Sentiment

Score: 3

Explanation: The company is in a critical fundraising stage, facing significant financial challenges (recurring losses, going concern doubt) and relying heavily on the IPO proceeds to fund essential clinical trials. While the market potential and patented technology are positive, the current financial state and the need for further capital raises for key indications present substantial risks.

Positives

Existing CE Mark approval allows commercialization in Europe and other international markets, providing current revenue streams.
Over 35,000 successful transcatheter defect closure implants globally demonstrate proven device design and clinical confidence.
FDA Investigational Device Exemption (IDE) approval for the PFO septal occlusion device for stroke in the US is a critical step towards market entry.
The PFO device offers distinct advantages over competitors, including ease of deployment, low metal mass, anatomical conformity, and low incidence of post-implant arrhythmia.
Significant market potential identified for PFO closure for stroke prevention (estimated over $1.5 billion annually in the US) and migraine relief (multi-billion-dollar opportunity).
The company possesses 9 granted and issued US patents pertaining to its septal occlusion products and technologies, with two key patents having remaining useful lives of 15 and 5 years.
Management believes the capital raised from the IPO, combined with anticipated revenues, will be sufficient to complete the stroke clinical trial through full regulatory approval.

Negatives

The company has incurred recurring net losses since inception, with a net loss of $1,845,951 in 2024 and $557,566 for the nine months ended September 30, 2025.
An accumulated deficit of $6,448,446 as of September 30, 2025, and negative working capital of $398,878 raise substantial doubt about the company's ability to continue as a going concern.
Revenue decreased by 16.4% for the nine months ended September 30, 2025, compared to the same period in 2024, attributed to focus on IPO fundraising and limited cash resources.
Clinical trial expenses decreased significantly in 2025 due to limited resources, highlighting funding constraints prior to the IPO.
The company has a material customer concentration, with one customer accounting for 73.8% of total accounts receivable as of September 30, 2025.
The net proceeds from this offering are not believed to be sufficient to complete a US trial for migraine indications through full regulatory approval, indicating a need for future capital raises.
Existing shareholders will experience immediate and substantial dilution of $3.80 per share from the IPO.

Risks

Inability to receive or delays in obtaining FDA approval for US market entry for PFO devices for stroke and migraine indications.
Clinical trial results may not be consistent with past experience or yield sufficient data for FDA approval.
Intense competition from large, well-established medical device manufacturers with greater resources and name recognition.
Potential for product liability claims due to the manufacture and sale of implantable medical devices, with insurance coverage potentially being inadequate.
Dependence on key members of senior management and the ability to attract and retain qualified personnel.
Challenges in managing anticipated growth, which could lead to delays, quality control issues, or increased costs.
Market for septal occlusion devices may not grow as expected due to clinical skepticism, alternative treatments, or reimbursement limitations.
Adverse impact on financial results from foreign currency fluctuations and potential new or increased tariffs.
Reliance on a single manufacturing facility, making operations vulnerable to disruptions from natural disasters or other events.
Dependence on vendors, consultants, and Clinical Research Organizations (CROs) for product development, manufacturing, and regulatory efforts.
Need for significant additional capital to implement a direct sales and marketing team in the US, with no assurance of success.
Potential for IT system failures, cyberattacks, or data breaches, which could harm business operations and financial condition.
Regulatory reforms in the EU could make it more difficult and costly to market or distribute products.
Inability to enforce intellectual property rights against infringement or to defend against claims of infringing others' rights.
Uncertainty regarding third-party reimbursement for products in the US and international markets, which is critical for commercial success.
Future pandemics could disrupt supply chains, clinical trials, and decrease demand for elective medical procedures.
Increased costs and diversion of management attention due to public company reporting requirements and compliance with Sarbanes-Oxley Act.
An active, liquid trading market for common stock may not develop or be sustained after the offering, leading to price volatility.
Officers and directors will retain significant ownership (29.0% post-offering), influencing shareholder matters.
Anti-takeover laws and provisions in governing documents could impede or diminish the value of a sale of the company.
Broad discretion of management in the use of net proceeds from the offering.
Inability to meet debt obligations, with a $1,000,000 secured loan maturing in 2026 and unsecured convertible notes also maturing in 2026.
Existing lender (Merit Medical Systems, Inc.) holds a right of first offer on future equity or debt financings and strategic transactions until November 6, 2028, which could limit flexibility.

Future Outlook

Encore Medical expects to incur net losses for the foreseeable future as it continues significant clinical and development expenses. The company plans to use IPO proceeds to fund its US clinical trials for stroke and migraine indications, with the stroke trial expected to take 18-24 months to complete. While the IPO proceeds are expected to be sufficient for the stroke trial through full regulatory approval, additional capital will likely be needed for later-stage migraine trials. The company aims to develop and utilize a direct sales and marketing team in the US once its PFO device is approved for sale and expects its gross profit percentage to increase over the long term as revenue grows.

Management Comments

Management believes that the proceeds allocated to these clinical programs will be sufficient to support ongoing clinical trial activities and to advance these programs through key development milestones.
Management does not believe that the net proceeds from this offering alone will be sufficient to complete a U.S. trial for migraine indications through full regulatory approval.
Management currently plans to seek additional equity financing; however, there is no assurance that this effort will be successful or sufficient to sustain operations beyond the next fiscal year.
Management believes its present facilities are in good condition, adequate for current operations, and provide ample capacity to scale up.

Industry Context

Encore Medical operates in the highly competitive and heavily regulated medical device industry, specifically focusing on structural heart devices for cardiac defects. The market is characterized by rapid technological change and intense competition from larger, established players like Abbott Laboratories and W. L. Gore & Associates. While the company has a CE Mark for European sales, it is currently seeking FDA approval to enter the lucrative US market, where competitors already have approved PFO devices. The PFO closure market for stroke prevention and migraine relief is considered to be in its infancy in the US, with significant growth potential following recent reimbursement establishment and clinical trial successes by competitors.

Comparison to Industry Standards

Encore's PFO device is positioned as superior to competing first-generation devices from companies like Abbott and Occlutech AB, citing features such as less metal, flatter profile, self-loading, full retrievability, lower cardiac arrhythmias, and easier future septal puncture procedures.
A peer-reviewed dual-center study (Becker et al., Clinical Cardiology, 2021) reported lower post-implant arrhythmia rates with the Encore PFO device, suggesting a strong safety profile compared to competitors.
The average retail price for PFO devices in the United States is approximately $11,000, which Encore's products would target upon FDA approval, aligning with established market pricing for competitors.
The company's current market penetration is limited to approximately 20 countries outside the US, primarily in Europe, where it competes with global players but lacks US FDA approval, a key differentiator for market share in the largest medical device market.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President & Chief Executive Officer	N/A	Joseph A. Marino	2024	Appointment to the role
Senior Vice President, Director	N/A	Peter M. Buonomo	2025	Appointment to the role
Director	N/A	Timothy G. Laske, PhD	2025	Appointment to the role

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	The board of directors will establish an audit committee, a governance committee, and a compensation committee prior to the completion of this offering.	Prior to completion of offering	Enhances corporate oversight and compliance with public company standards.
Audit Committee Independence	Mr. Marino will be replaced as a member of the audit committee by Mr. Laske within 12 months to meet independence requirements.	Within 12 months of offering completion	Strengthens audit committee independence and compliance with listing standards and Rule 10A-3(b)(1) of the Exchange Act.
Governance Committee Independence	Mr. Marino will be replaced as a member of the governance committee by Mr. Laske within 12 months to meet independence requirements.	Within 12 months of offering completion	Enhances governance committee independence and compliance with listing standards.
Compensation Committee Independence	Mr. Marino will be replaced by Mr. Laske as a compensation committee member within 12 months to ensure continued compliance with independence under listing standards.	Within 12 months of offering completion	Strengthens compensation committee independence and compliance with listing standards.
Series A Preferred Stock Rights	Upon conversion of all Series A Preferred Stock in connection with this offering, the board representation right of Series A holders will terminate.	Immediately prior to offering closing	Removes a specific board representation right, potentially altering board dynamics and increasing common shareholder influence over director elections.
Authorized Capital Stock	Authorized common shares increased from 10,000,000 to 20,000,000 shares; total authorized capital stock increased to 24,000,000 shares (20M common, 4M preferred).	November 17, 2025	Provides greater flexibility for future equity issuances, including for capital raises, acquisitions, and employee benefit plans, but also increases potential for dilution.
Code of Business Conduct and Ethics	The company intends to adopt a Code of Conduct and Ethics applicable to all employees, officers, and directors.	In connection with this offering	Establishes formal ethical guidelines and compliance framework for a public company.

Legal Proceedings

The company is not a party to any pending legal proceedings.
No directors, officers, or affiliates are involved in proceedings adverse to the business or have a material interest adverse to the business.

Related Party Transactions

The company has common ownership with Cardia, Inc., including the same CEO (Joseph Marino) and two board members (Joseph Marino, Peter Buonomo, Christopher J. Turnbull).
Cardia, Inc. sold and remitted sales proceeds of $888,342 in 2024 and $0 for the nine months ended September 30, 2025, to Encore Medical.
Encore Medical purchased contract manufacturing services from Cardia, Inc. for $388,289 in 2023 and contract management services for $130,310 in 2024.
Encore Medical has an agreement to manufacture medical devices for Cardia, billing Cardia $27,650 in 2024 and $19,006 for the nine months ended September 30, 2025.
As of December 31, 2024, Encore had a $0 receivable from Cardia, Inc., down from $381,727 at December 31, 2023, after recording a $475,538 bad debt expense in 2024 due to Cardia's limited revenue expectations.
As of September 30, 2025, Encore had a payable due to Cardia of $65,499.
On May 15, 2025, Encore obtained a $200,000 line of credit with Cardia, Inc., with $170,753 drawn as of September 30, 2025, bearing 6% interest and maturing May 15, 2026.
Christopher J. Turnbull, a board member, holds a $50,000 unsecured promissory note with Encore, amended November 24, 2025, bearing 10% interest and maturing June 30, 2026, convertible into common stock at $5.00 per share.
Joseph A. Marino, CEO, holds an unsecured promissory note for $200,000, dated November 24, 2025, bearing 10% interest and maturing June 30, 2026, convertible into common stock at $5.00 per share.
All related-party transactions are reviewed and approved in accordance with the company's related party agreements.

Stakeholder Impact

Shareholders: Will experience immediate and substantial dilution from the IPO. Existing officers and directors will retain significant voting influence. Future capital raises may cause further dilution. The ability to realize a return on investment depends on stock price appreciation, as no dividends are planned.
Employees: The company's ability to attract and retain qualified personnel is critical for business success and growth. Stock options are part of executive compensation, aligning interests with company performance.
Customers: Continued product development and regulatory approvals, particularly in the US, could expand product availability and treatment options for cardiac defects. However, customer concentration poses a risk if major customers are lost or payments are delayed.
Suppliers/Vendors: The company is dependent on third-party vendors for certain components and services, and disruptions could impact product development and manufacturing.
Creditors: The company has significant indebtedness, including a secured loan, and its ability to repay these obligations depends on successful capital raises and operational performance. A default could lead to asset seizure by secured creditors.

Next Steps

Complete the US clinical trial for the PFO septal occlusion device for stroke, expected to take 18-24 months.
Submit a PMA application to the FDA for final approval of the PFO device for stroke after successful clinical trial completion.
Continue conducting the clinical study outside the US for the migraine indication.
Apply for US FDA IDE approval to conduct a US clinical trial for the PFO device for migraine treatment upon successful conclusion of the ex-US study.
Develop and utilize a direct sales and marketing team in the United States once the PFO device is approved for sale.
Maintain the listing of common stock on the NYSE American for at least three years after the Closing Date.
Implement additional finance and accounting systems, procedures, and controls to satisfy public company reporting requirements.
Address material weaknesses in internal controls over financial reporting related to financial close and reporting, inventory valuation, and document retention.
Seek additional equity or debt financing as needed to fund operations, clinical trials, or commercialization efforts, particularly for later-stage migraine trials.

Key Dates

Date	Description
1972	Joseph A. Marino graduated from the University of Minnesota with a Bachelor of Science degree.
1977	Joseph A. Marino served as Director and Department Head of various clinical services at the University of Minnesota Hospitals.
1979	Christopher J. Turnbull graduated from Saint Mary's School of Nurse Anesthesiology.
1980	Joseph A. Marino served as Chairman of the Board of Directors and President and Chief Executive Officer of Biomedical Dynamics Corporation; Christopher J. Turnbull became a Board-Certified Registered Nurse Anesthetist (CRNA).
1983	Peter Buonomo graduated from Oral Roberts University with a Bachelor of Science in Business.
1984	Peter Buonomo completed his MBA at Oral Roberts University.
1986	Christopher J. Turnbull founded and served as CEO of Critical Care Anesthetists, PA.
1993	Christopher J. Turnbull was Chairman and CEO of St. Paul Medical, Inc.
1994	Joseph A. Marino served as Chairman and CEO of Applied Biometrics, Inc.; Peter Buonomo was Director of Marketing and VP of Sales and Marketing at Applied Biometrics, Inc.
1996	Joseph A. Marino joined the Electro-Sensors, Inc. board.
1998	Joseph A. Marino served as Chairman of the Board of Directors and Chief Executive Officer of Cardia, Inc.; Peter Buonomo was VP of Sales and Marketing and a Corporate Officer at Cardia, Inc.; Christopher J. Turnbull served as a Director of Cardia, Inc.
2000	Todd C. Johnson graduated from Southern Methodist University with a Bachelor of Science in Finance.
2001	Christopher J. Turnbull served as Chairman and CEO of T Medical, Inc.
2005	Christopher J. Turnbull served as CEO of Owatonna Anesthesia Services P.A.
2006	Patent #7,115,135 ('Occlusion Device with Non-Thrombogenic Properties') issued.
2009	Patent #7,582,104 ('Daisy Design for Occlusion Device') issued.
2010	Patent #7,658,748 ('Right Retrieval Mechanism') and Patent #7,691,115 ('Occlusion Device with Flexible Fabric Connector') and Patent #7,749,238 ('Occlusion Device with Flexible Polymeric Connector') issued.
2010	Scott S. Robinson served as Controller of Cardia, Inc.
2012	Patent #6,379,368 ('Occlusion Device with Non-Thrombogenic Properties') expired.
2013	Joseph A. Marino became Chairman of Electro-Sensors, Inc.; Patent #8,366,741 ('Occlusion Device with Centering Arm') issued.
2015	Christopher J. Turnbull founded and served as CEO of Minnesota Anesthesia Associates, PLC (MAA); Christopher J. Turnbull provided anesthesia services to the Mayo Clinic.
2016	St. Jude Medical (now Abbott) was awarded FDA approval to begin marketing its PFO products in the United States (October 28).
2017	Encore Medical, Inc. was incorporated as a Minnesota corporation (September 26); Christopher J. Turnbull served as the lead CRNA for Twin Cities Surgery Center; Encore Medical, Inc. 2018 Stock Incentive Plan adopted by board of directors (December 1).
2018	Encore Medical, Inc. 2018 Stock Incentive Plan became effective (January 16); Joseph A. Marino served as Chairman of the Board of Directors of the Company; Scott S. Robinson became Treasurer and VP of Finance of the Company; Peter Buonomo became Vice President of Sales and Marketing at the Company; Scott S. Robinson granted option to purchase 25,000 shares of common stock (June 5); Christopher J. Turnbull granted option to purchase 50,000 shares of common stock (June 5).
2019	Medical reimbursement for PFO closure established in the U.S. (late).
2020	Encore Medical ceased to be a subsidiary of Cardia, Inc. via a tax-free spin-off (October 1); Christopher J. Turnbull retired from Nurse Anesthesia practice.
2021	Todd C. Johnson served as a Director of the Company.
2022	Patent #7,582,104 ('Daisy Design for Occlusion Device') and Patent #7,115,135 ('Occlusion Device with Non-Thrombogenic Properties') expired; Series A Preferred Stock issued to accredited investors in a series of closings; 472,000 warrants issued with $10.00 exercise price expiring 2029; 37,760 warrants issued with $5.00 exercise price expiring 2032.
2022	FDA granted Investigational Device Exemption (IDE) approval to commence Class III clinical trials in the United States for PFO septal occlusion devices (September 7).
2023	Company entered into a lease for office, manufacturing, and warehouse space (February 3); First Amendment to Commercial Lease effective (March 3); Commencement Date of lease anticipated (April 1); Encore's PFO IDE trial received CMS Category B IDE coverage approval (April); Company began manufacturing its own product (2023); Loan Agreement with Merit Medical Systems, Inc. for $1 million loan (November 6); Christopher J. Turnbull's $50,000 unsecured promissory note obtained (October 11); Scott S. Robinson's employment began (December 1); Patent #11,771,411 ('PFO Device') issued (October 3).
2024	Company adopted ASU 2023-07 Improvements to Reportable Segment Disclosures (January 1); Joseph A. Marino's employment began (April 4); Peter M. Buonomo's employment began (April 4); Joseph A. Marino granted options to purchase 50,000 shares of common stock (August 15); Christopher J. Turnbull granted option to purchase 50,000 shares of common stock (August 15); Peter M. Buonomo granted options to purchase 125,000 shares of common stock (August 15); Scott S. Robinson granted options to purchase 75,000 shares of common stock (August 15); Company issued 81,000 shares of common stock to accredited investors in a series of closings; Contract Sales and Manufacturing Agreement with Cardia, Inc. effective (November 15); Greg Steiner served as Advisor to the Board.
2025	Company obtained a $200,000 line of credit with Cardia, Inc. (May 15); Christopher J. Turnbull's unsecured promissory note amended and restated (November 24); Joseph A. Marino obtained unsecured promissory note for $200,000 (November 24); 1915 Florida Investment Corp obtained unsecured promissory note for $100,000 (December 10); Registration Statement on Form S-1 filed with the SEC (December 30); Auditor's report dated (September 4); Consent of Boulay PLLP dated (December 29).
2026	Underwriters expect to deliver common stock to purchasers (approximate date); Christopher J. Turnbull's unsecured promissory note matures (June 30); Joseph A. Marino's unsecured promissory note matures (June 30); 1915 Florida Investment Corp's unsecured promissory note matures (June 30); Loan Agreement with Merit Medical Systems, Inc. matures (November 6).
2028	Encore Medical, Inc. 2018 Stock Incentive Plan terminates (January 15); Merit Medical Systems, Inc.'s right of first offer expires (November 6); Contract Sales and Manufacturing Agreement with Cardia, Inc. extended through (December 31).
2029	Lease for office, manufacturing, and warehouse space terminates (May 31); Warrants issued in 2022 with $10.00 exercise price expire.
2030	Patent #8,366,741 ('Occlusion Device with Centering Arm') expires.
2031	Warrants issued in 2021 with $5.00 exercise price expire.
2032	Warrants issued in 2022 with $5.00 exercise price expire.
2034	Stock options granted to Joseph A. Marino and Peter M. Buonomo expire (August 15).
2040	Patent #11,771,411 ('PFO Device') expires.

Recommendation

hold

Encore Medical is at a pivotal stage, seeking to raise capital through an IPO to fund critical US clinical trials for its PFO devices. While the potential market for its structural heart devices is substantial, and the company has a proven track record in international markets with CE Mark approval, its current financial health is concerning, marked by recurring net losses and a going concern qualification from its auditor. The success of the IPO and subsequent FDA approvals are paramount for the company's viability and growth. Given the high degree of risk associated with clinical trials, regulatory hurdles, intense competition, and the immediate dilution for new investors, a 'hold' recommendation is appropriate. Investors should monitor the progress of clinical trials, FDA approval, and the company's ability to achieve profitability and secure additional financing for its migraine indication before considering further investment.

Keywords

Medical Devices, Structural Heart, PFO Closure, ASD Closure, IPO, SEC Filing, Clinical Trials, FDA Approval, CE Mark, Cardiology, Stroke Prevention, Migraine Treatment, Underwriting Agreement, Going Concern, Dilution, Intellectual Property, Healthcare Regulation, Biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.